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Abstract
Background: Endocarditis is a common complication in Staphylococcus aureus bacteremia (SAB).
We compared risk factors, clinical manifestations, and outcome in a large, prospective cohort of
patients with S. aureus endocarditis in injection drug users (IDUs) and in nonaddicts.
Methods:  Four hundred and thirty consecutive adult patients with SAB were prospectively
followed up for 3 months. Definite or possible endocarditis by modified Duke criteria was found
in 74 patients: 20 patients were IDUs and 54 nonaddicts.
Results: Endocarditis was more common in SAB among drug abusers (46%) than in nonaddicts
(14%) (odds ratio [OR], 5.12; 95% confidence interval [CI], 2.65–9.91; P < 0.001). IDUs were
significantly younger (27 ± 15 vs 65 ± 15 years, P < 0.001), had less ultimately or rapidly fatal
underlying diseases (0% vs 37%, P < 0.001) or predisposing heart diseases (20% vs 50%, P = 0.03),
and their SAB was more often community-acquired (95% vs 39%, P  < 0.001). Right-sided
endocarditis was observed in 60% of IDUs whereas 93% of nonaddicts had left-sided involvement
(P < 0.001). An extracardiac deep infection was found in 85% of IDUs and in 89% of nonaddicts (P
= 0.70). Arterial thromboembolic events and severe sepsis were also equally common in both
groups. There was no difference in mortality between the groups at 7 days, but at 3 months it was
lower among IDUs (10%) compared with nonaddicts (39%) (OR, 5.73; 95% CI, 1.20–27.25; P =
0.02).
Conclusion:  S. aureus endocarditis in IDUs was associated with as high complication rates
including extracardiac deep infections, thromboembolic events, or severe sepsis as in nonaddicts.
Injection drug abuse in accordance with younger age and lack of underlying diseases were
associated with lower mortality, but after adjusting by age and underlying diseases injection drug
abuse was not significantly associated with mortality.
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Background
Bacteremic infections caused by Staphylococcus aureus have
been reported with increasing frequency, and it has
emerged as a leading cause of infective endocarditis (IE)
in many regions of the world [1-3]. Endocarditis has been
observed in 11% to 35% of S. aureus bacteremias (SAB)
attributable to different sets of diagnostic criteria [4-6]. S.
aureus endocarditis is associated with higher occurrence of
extracardiac deep infections due to metastatic spread,
thromboembolic complications, and a high mortality
compared with IE caused by other pathogens [1,2].
The incidence of endocarditis has not been changed dur-
ing the past two decades [7,8] but classic risk factors such
as rheumatic heart disease are being replaced by new
groups, including injection drug users (IDUs), elderly
patients with degenerative valve disease, patients with
intravascular catheter or prosthetic valve, and nosocomial
acquisition [2,3,8]. One of the reasons for increased inci-
dence of S. aureus in IE is injection drug abuse [9-11]. Col-
onization  with S. aureus, HIV-related
immunosuppression, female sex, increasing injection
drug use frequency, and a history of previous IE are asso-
ciated with a higher risk for endocarditis [11,12].
Right-sided involvement, younger age, and lack of pre-
existing heart disease or other underlying diseases have
been thought to explain the better prognosis of S. aureus
endocarditis among IDUs than in general population
[2,13-15]. Therefore, surgery is less frequently needed and
shorter antibiotic courses have been used in IDUs [16,17].
Drug abusers tend to have fewer arterial embolic events or
strokes than nonaddicts [13,18]. These differences
between IDUs and general population have been derived
from non-comparative trials, and there are only few stud-
ies where the clinical picture of S. aureus endocarditis in
these patient groups has been compared [2,13,14,19].
We collected prospectively a large patient population with
SAB and compared the risk factors, clinical, and echocar-
diographic findings as well as outcome of endocarditis in
IDUs and in general population.
Methods
Patient population
Prospectively randomized adult patients with blood cul-
ture positive for S. aureus from 5 university hospitals and
7 tertiary care hospitals in Finland were taken into the trial
from January 1999 to May 1999 and from January 2000
to August 2002. Originally, the trial was designed for eval-
uation on the effect of fluoroquinolone (trovafloxacin or
levofloxacin) given in addition to most effective standard
treatment in SAB [20] [see Additional file 1]. Clinical,
pathological, and echocardiographic data of patients with
definite or possible IE according to modified Duke criteria
were collected [21], and these cases were included into the
analysis. The protocol was approved by the ethics com-
mittees of all study sites, and written informed consent
was obtained from all patients or their representatives.
The trial was conducted in accordance with the Declara-
tion of Helsinki.
The exclusion criteria were age younger than 18 years,
imprisonment, proven or suspected pregnancy, breast-
feeding, epilepsy, another bacteremia during the previous
28 days, polymicrobial bacteremia (≥ 3 microbes), history
of allergy to any quinolone antibiotic, previous tendinitis
during fluoroquinolone therapy, prior fluoroquinolone
use for more than 5 days before randomization, positive
culture for S. aureus only from a central intravenous cath-
eter, meningitis, neutropenia (< 0.5 × 109/L), or failure to
supply an informed consent. Patients with bacteremia due
to methicillin-resistant S. aureus (MRSA) and a S. aureus
strain resistant to any fluoroquinolone were also
excluded.
Definitions
IDUs were defined as patients who had injected drugs
within the past 6 months before randomization. Routine
bacteriological methods were used to detect S. aureus
growth in blood [20] [see Additional file 1]. Bacteremia
was hospital-acquired if the first positive blood culture
was obtained ≥ 48 hours after admission, or the patient
was a resident in a long-term care facility or attended
hemodialysis within the preceding 2 months. Prognosis
or severity of underlying diseases were classified as
healthy, nonfatal, ultimately, or rapidly fatal according to
the criteria of McCabe and Jackson [22]. Severe sepsis at
the time of first blood culture positive for S. aureus was
defined as an infectious process leading to organ dysfunc-
tion or signs of hypoperfusion or hypotension [23].
The infection focus was documented by clinical, bacterio-
logical, radiological, or pathological investigations. Intra-
venous catheter-associated bacteremia was defined using
the guidelines of the Infectious Diseases Society of Amer-
ica [24]. Extracardiac deep infection was defined as pneu-
monia, deep-seated abscess, osteomyelitis, septic arthritis,
meningitis, septic thrombophlebitis, mediastinitis, uri-
nary tract infection, infection of any extracardiac pros-
thetic device, or recurrent SAB. Clinical findings of IE such
as documentation of a new valvular regurgitant murmur,
or evidence of any vascular phenomena such as infarction
and embolic event or intracranial hemorrhage were
detected. Endocarditis of prosthetic valve was classified as
early when occurring ≤ 60 days after valve replacement
and as late > 60 days after valve replacement. Leucocytosis
was determined if white blood cell count was over 12 ×
109/L and leucopenia less than 4 × 109/L.BMC Infectious Diseases 2006, 6:137 http://www.biomedcentral.com/1471-2334/6/137
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Echocardiography
Two-dimensional imaging from multiple tomographic
planes and spectral Doppler and color flow imaging were
used in all study sites. Transthoracic echocardiography
(TTE) and/or transesophageal echocardiography (TEE) as
clinically indicated were performed at the discretion of the
treating physician and by experienced echocardiogra-
phers. The presence of cardiac vegetations, oscillation,
paravalvular or intracardiac abscess, new valvular regurgi-
tation, prosthetic valve dehiscence, and valve perforation
were recorded [21].
Antibiotic treatment
The detailed information of the antimicrobial agents,
doses, indications and duration of treatment have been
described in our former article [20] [see Additional file 1].
All patients with endocarditis were assigned to receive ini-
tially cloxacillin or dicloxacillin (2 g q4 h) for 4 to 6 weeks
intravenously. Alternatively, cefuroxime (1.5 g q6 h) or
vancomycin (1 g bid) were allowed if a contraindication
against the use of semisynthetic penicillins was noted.
Aminoglycoside (either tobramycin or netilmicin at 1 mg/
kg of body weight q8h) was added to the drug therapy
described above for the first 7 days. Rifampicin (450 mg
once daily for patients under 50 kg and 600 mg once daily
for patients over 50 kg in weight, orally or intravenously)
was recommended for at least 4 weeks when an endocar-
ditis or an extracardiac deep infection was suspected or
confirmed. Half of the patients were randomized to
receive a fluoroquinolone either trovafloxacin or levo-
floxacin in addition to therapy above. Fluoroquinolone
treatment was not observed to have an impact on mortal-
ity in SAB or in patients with IE [20] [see Additional file
1]. In cases of renal dysfunction the antibiotic doses were
adjusted as recommended by the manufacturers.
Clinical outcome
All patients were prospectively followed for 3 months
after the first positive blood culture for S. aureus. Case
fatality rates were recorded at 7 days and 28 days, and at 3
months. Other outcome measures were site of valvular
involvement, evidence of extracardiac deep infections or
thromboembolic events, duration of fever (recorded in
days until axillary temperature was < 37.5 C°), duration
of hospitalization and need for cardiac surgery. Labora-
tory tests were conducted on the day of the first positive
blood culture for S. aureus.
Statistical analysis
Statistical analyses were performed with SPSS® version
12.0. (SPSS Inc., Chicago, IL, USA). Univariate analyses
for categorical variables were calculated with chi-square
test or Fisher's exact test as appropriate, and for continu-
ous variables the Mann-Whitney test was used. Odds
ratios (OR) with 95% confidence intervals (CI) were as
association measures. Cox regression analysis was used to
compare survival of IDUs with nonaddicts, and results
were given as hazard ratios (HR) with 95% CI. Survival
was calculated from the day of the first blood culture pos-
itive for S. aureus until 3 months. All tests were 2-tailed
and P values of < 0.05 were considered significant.
Results
Patient characteristics
During the study period, 430 patients with S. aureus bac-
teremia were included into this trial. The included
patients represented 31% of all SAB patients in study hos-
pitals. Endocarditis was observed in 74 of 430 patients
(17%), of whom 20 were IDUs and 54 were nonaddicts.
Thus, IE was observed in 46% of all 44 IDUs and in 14%
of all 386 nonaddicts with SAB (OR, 5.12; 95% CI, 2.65–
9.91; P < 0.001). Patients with endocarditis differed from
those with SAB only by having significantly more often a
predisposing heart disease or a pre-existing liver disease
(chronic hepatitis C infection in 19 patients and hepatic
cirrhosis in 5 patients), but less preceding trauma (Table
1). Other predisposing characteristics and underlying dis-
eases of the patients with IE did not differ from those with
SAB.
Among patients with endocarditis, IDUs as a group were
younger and had less predisposing heart conditions, cor-
onary artery disease or diabetes than nonaddicts (Table
2). When the underlying diseases were grouped by the
predicted prognoses (McCabe's classification), none
among the IDUs had a rapidly fatal or ultimately fatal dis-
ease but they were found in 20 of 54 nonaddicts (37%) (P
= 0.001). However, there were three IDUs with HIV infec-
tion.
Only one drug abuser had a hospital-acquired bacteremia
and none associated with the use of the central intrave-
nous catheter (Table 2). Severe sepsis was observed in 9 of
20 IDUs (45%) and in 28 of 54 nonaddicts (52%) with-
out significant difference between the groups (P = 0.79).
Site of endocarditis
According to the modified Duke criteria for endocarditis,
56 patients (76%) were confirmed as definite (10 by path-
ologic criteria and 46 by clinical criteria), and 18 patients
(24%) as possible (Table 3). Left-sided involvement was
observed in 93% of nonaddicts whereas in 60% of IDUs
had right-sided endocarditis (tricuspid valve involvement
in all patients). Among nonaddicts aortic valve was
slightly more often involved (44%) than mitral valve
(35%).
Prosthetic valve endocarditis, involving left side only,
occurred in 17 of 74 patients (23%) and they all presentedBMC Infectious Diseases 2006, 6:137 http://www.biomedcentral.com/1471-2334/6/137
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in nonaddicts. The most of these patients had an early
onset of prosthetic valve IE (12 patients).
Echocardiographic findings
Echocardiography was performed in 263 of 430 patients
(61%) with SAB. Addicts underwent echocardiography
significantly more often (91%) compared with nonad-
dicts (58%) (OR, 7.31; 95% CI, 2.56–20.84; P < 0.001).
In endocarditis, TTE was performed in 72 of 74 patients
(97%) with no significant difference between IDUs and
nonaddicts (Table 3). TEE was performed significantly
more often in nonaddicts than in IDUs (74% vs 45%).
A vegetation was evident by echocardiography in 53% of
cases and a new regurgitation in 71% of cases without sig-
nificant differences between the groups (Table 3). Only 4
patients had an intracardial abscess or valve perforation.
Clinical manifestations and outcome
There were no differences in the clinical manifestations
between the groups except the tendency for more frequent
occurrence of various vascular phenomena among IDUs
(Table 4). The most common infection focus was skin or
soft tissue infection in 46 of 74 patients (62%). An extrac-
ardiac deep infection was found in 85% of IDUs and in
89% of nonaddicts (P = 0.70).
Vascular complications, including arterial or venous
thromboembolic events, were detected in 60% of IDUs
but in only 35% of nonaddicts (P = 0.07) (Table 4). Espe-
cially, septic pulmonary embolism was observed only in
IDUs. Whereas all coronary artery related diseases were
among nonaddicts, all 3 parenchymal embolic events
were observed in drug abusers. Congestive heart failure in
acute phase was present in 11 of 74 patients (15%) with
no difference between the groups. Two patients developed
recurrent bacteremia during the 3 months follow-up
period. There were no differences in median duration of
fever (3 days) or median duration of hospitalization (32
days) between IDUs and nonaddicts (Table 5). Cardiac
surgery was performed in 15% of IDUs but only in 7% of
nonaddicts (OR, 2.21; 95% CI, 0.45–10.87; P = 0.38).
Case fatality rate of all patients with IE was 23% at 28
days, and 31% at 3 months (Table 5). Mortality was sig-
nificantly higher in nonaddicts than in addicts at 28 days
Table 1: Characteristics of 430 patients with Staphylococcus aureus bacteremia with and without endocarditis.
Bacteremia with endocarditis Bacteremia without endocarditis Total 
Characteristic (n = 74) (n = 356) (n = 430) OR 95% CI P
Age, mean years ± SD 55 ± 22 59 ± 17 58 ± 18 - - 0.26
Male sex 47 (64) 221 (62) 268 (62) 1.06 0.63–1.79 0.82
Hospital-acquired 34 (46) 198 (56) 232 (54) 0.68 0.41–1.12 0.13
Previous skin disease or wound 34 (46) 189 (53) 223 (52) 0.75 0.45–1.24 0.26
Previous surgerya 18 (24) 77 (22) 95 (22) 1.17 0.65–2.10 0.61
Trauma in prior 2 months 12 (16) 98 (28) 110 (26) 0.51 0.26–0.99 0.04
Central intravenous catheter 10 (14) 48 (14) 58 (14) 1.00 0.48–2.09 0.99
Hemodialysis 6 (8) 38 (11) 44 (10) 0.74 0.30–1.82 0.51
Previous S. aureus deep infection 3 (4) 28 (8) 31 (7) 0.50 0.15–1.67 0.33
Previous S. aureus bacteremia 2 (3) 15 (4) 17 (4) 0.63 0.14–2.82 0.75
Predisposing heart condition 47 (64) 63 (18) 110 (26) 8.10 4.69–13.98 <0.001
Degenerative heart disease 22 (30) 32 (9) 54 (13) 4.28 2.31–7.94 <0.001
Injection drug use 20 (27) 24 (7) 44 (10) 5.12 2.65–9.91 <0.001
Prosthetic valve 17 (23) 1 (0.3) 18 (4) 105.88 13.82–811.08 <0.001
Prior endocarditis 11 (15) 0 (0) 11 (3) - - <0.001
Congenital heart disease 5 (7) 5 (1) 10 (2) 5.09 1.43–18.05 0.02
Mitral valve prolapse 2 (3) 2 (1) 4 (1) 4.92 0.68–35.48 0.14
Rheumatic heart disease 2 (3) 1 (0.3) 3 (1) 9.86 0.88–110.21 0.08
Coronary artery disease 21 (28) 89 (25) 110 (26) 1.19 0.68–2.08 0.54
Corticosteroid use ≥ 1 month 8 (11) 37 (10) 45 (11) 1.05 0.47–2.35 0.92
Immunosuppressive therapyb 3 (4) 26 (7) 29 (7) 0.54 0.16–1.82 0.45
Diabetes 19 (26) 89 (25) 108 (25) 1.04 0.58–1.84 0.90
Alcoholism 4 (5) 44 (12) 48 (11) 0.41 0.14–1.17 0.10
Liver disease 24 (32) 43 (12) 67 (16) 3.49 1.95–6.25 <0.001
Malignancy 9 (12) 54 (15) 63 (15) 0.77 0.36–1.65 0.51
Chronic renal failure 8 (11) 52 (15) 60 (14) 0.71 0.32–1.56 0.39
HIV positive 3 (4) 5 (1) 8 (2) 2.97 0.69–12.70 0.14
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a Includes cardiac and non-cardiac surgery during 3 months preceding the positive blood culture.
b During 6 months preceding the positive blood culture.BMC Infectious Diseases 2006, 6:137 http://www.biomedcentral.com/1471-2334/6/137
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(OR, 8.00; 95% CI, 0.99–64.94; P = 0.03), and also at 3
months (OR, 5.73; 95% CI, 1.20–27.25; P = 0.02). Signif-
icant factors for lower mortality based on univariate anal-
yses were injection drug abuse (HR, 0.22; 95% CI, 0.05–
0.92; P = 0.04), age (HR, 1.03; 95% CI, 1.01–1.06; P =
0.006), and none or nonfatal underlying diseases by
McCabe's classification (HR, 0.24; 95% CI, 0.10–0.54; P =
0.001). Statistically significant association for mortality
were not found with the following: right-sided involve-
ment (HR, 0.30; 95% CI, 0.07–1.30; P = 0.11), left-sided
involvement (HR, 2.31; 95% CI, 0.69–7.78; P = 0.18),
severe sepsis at the time of first positive blood culture for
S. aureus (HR, 1.71; 95% CI, 0.74–3.95; P = 0.21), or arte-
rial embolic events (HR, 2.15; 95% CI, 0.94–4.90; P =
0.07). After adjusting by age and underlying diseases,
injection drug abuse was not significantly associated with
lower mortality (HR, 0.74; 95% CI, 0.10–5.40; P = 0.77).
Laboratory data
At the time of first positive blood culture for S. aureus, leu-
cocytosis was significantly more common in nonaddicts
than in IDUs (55% vs 15%, respectively; P = 0.003), and
only 2 patients (4%) had leucopenia. The median of
serum C-reactive protein on the day of the first positive
blood culture for S. aureus was 198 mg/L (range, 60–413
mg/L) in addicts compared with 171 mg/L (range, 5–478
mg/L) in nonaddicts without significant difference
between the groups. Only 2 nonaddicts and none of IDUs
had alanine aminotransferase level 2-fold above normal
limit.
Antibiotic treatment
Sixty-five of 74 patients (88%) were treated with cloxacil-
lin or dicloxacillin with no significant difference between
the groups. Seven patients (10%) received cefuroxime,
and one received vancomycin and one ceftriaxone. The
median duration of parenteral antibiotic therapy from the
first positive blood culture for S. aureus was 30 days (inter-
quartile range, 24–43 days) in IDUs and 26 days (inter-
quartile range, 13–34 days) in nonaddicts (P  = 0.12),
respectively.
An aminoglycoside was significantly more often given to
addicts (19 of 20 patients) than to nonaddicts (29 of 54
Table 2: Characteristics of injection drug users and nonaddicts with Staphylococcus aureus endocarditis.
Injection drug users Nonaddicts 
Characteristic (n = 20) (n = 54) P
Age, mean years ± SD 27 ± 15 65 ± 15 <0.001
Male sex 15 (75) 32 (59) 0.28
Hospital-acquired 1 (5) 33 (61) <0.001
Previous skin disease or wound 12 (60) 22 (41) 0.19
Previous surgerya 0 (0) 18 (33) 0.002
Trauma in prior 2 months 3 (15) 9 (17) 1.00
Central intravenous catheter 0 (0) 10 (19) 0.05
Hemodialysis 0 (0) 6 (11) 0.18
Previous S. aureus deep infection 2 (10) 1 (2) 0.18
Previous S. aureus bacteremia 2 (10) 0 (0) 0.07
Predisposing heart condition 4 (20) 27 (50) 0.03
Degenerative heart disease 0 (0) 22 (41) <0.001
Prosthetic valve 0 (0) 17 (32) 0.004
Prior endocarditis 1 (5) 10 (19) 0.27
Congenital heart disease 3 (15) 2 (4) 0.12
Mitral valve prolapse 0 (0) 2 (4) 1.00
Rheumatic heart disease 0 (0) 2 (4) 1.00
Coronary artery disease 0 (0) 21 (39) <0.001
Corticosteroid use ≥ 1 month 0 (0) 8 (15) 0.10
Immunosuppressive therapyb 0 (0) 3 (6) 0.56
Diabetes 1 (5) 18 (33) 0.02
Alcoholism 0 (0) 4 (7) 0.57
Liver disease 18 (90) 6 (11) <0.001
Chronic hepatitis C 17 (85) 2 (4) <0.001
Hepatic cirrhosis 1 (5) 4 (7) 1.00
Malignancy 0 (0) 9 (17) 0.10
Chronic renal failure 0 (0) 8 (15) 0.10
HIV positive 3 (15) 0 (0) 0.02
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a Includes cardiac and non-cardiac surgery during 3 months preceding the positive blood culture.
b During 6 months preceding the positive blood culture.BMC Infectious Diseases 2006, 6:137 http://www.biomedcentral.com/1471-2334/6/137
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patients) (OR, 16.38; 95% CI, 2.05–131.21; P = 0.001).
Eighteen of 20 IDUs (90%) received rifampicin compared
with 48 of 54 nonaddicts (89%) with no significant differ-
ence between the groups.
Discussion
To the best of our knowledge, this trial is one of the largest
prospective evaluations on S. aureus endocarditis compar-
ing patients with and without injection drug use [2,13]. It
is to be noted that our trial included only methicillin-sen-
sitive S. aureus (MSSA) strains. MRSA strains are very rare
in Finland (< 2% from all isolated S. aureus strains) and
not a single endocarditis due to MRSA had to be excluded.
Lack of MRSA might complicate extrapolation of these
results into countries with high MRSA prevalence. How-
ever, MRSA endocarditis is usually more difficult to treat.
While concentrating only on cases caused by MSSA strains
real differences between IDUs and nonaddicts might be
better revealed. In our trial, right-sided involvement pre-
dominated slightly in IDUs whereas almost all nonaddicts
had left-sided endocarditis. In contrast to previous data
the frequency of complications among IDUs was equal to
that among nonaddicts. An extracardiac deep infection
was observed also in most of the addicts. According to
recent studies, deep infections seem to be more common
in SAB than previously thought [20,25] [see Additional
file 1]. In the current trial, the frequency of arterial
embolic events was similar in both groups, although they
have been observed less frequently among IDUs in earlier
studies [13,18,26]. However, mortality in addicts was sig-
nificantly lower than in nonaddicts as reported previously
[13,14,26,27].
S. aureus is an important and a more common cause of IE,
especially among IDUs [8,11]. In a recent prospective
multicenter study of 505 patients with SAB, endocarditis
was found in 13% of all patients and in 35% of IDUs [6].
In agreement with that study, the incidence of IE was 17%
among all SAB patients and 46% among IDUs in our trial.
The proportion of definite IE in the present trial (76%)
was also in line that observed in the other large survey [6].
Frequent use of echocardiography may increase the inci-
dence of IE at least to some extent. Persistent bacteremia
for over 3 days has been suggested to be a predictor for
endocarditis [28] which was not designed for evaluation
in our trial. We performed echocardiography as clinically
indicated. It was done to 61% of SAB patients, and the rate
was similar or higher compared with other studies
[19,25,29]. Some endocarditis cases with atypical presen-
tation might have been missed because echocardiography
in our cohort as well as in previous studies was not per-
formed for all SAB patients. The tricuspid valve was pre-
dominantly affected in addicts (60%), although the
Table 3: Classification, valvular involvement and echocardiographic findings of injection drug users and nonaddicts with Staphylococcus 
aureus endocarditis.
Injection drug users Nonaddicts Total
Variable (n = 20) (n = 54) (n = 74) OR 95% CI P
Criteria, classificationa
Possible 1 (5) 17 (32) 18 (24) 0.12 0.01–0.93 0.03
Definite 19 (95) 37 (69) 56 (76) 8.73 1.08–70.67 0.03
Valvular involvementb
Left-sided 6 (30) 50 (93) 56 (76) 0.03 0.01–0.14 <0.001
Aortic 2 (10) 24 (44) 26 (35) 0.14 0.03–0.66 0.006
Mitral 3 (15) 19 (35) 22 (30) 0.33 0.08–1.25 0.15
Aortic and mitral 1 (5) 7 (13) 8 (11) 0.35 0.04–3.07 0.44
Right-sided 12 (60) 4 (7) 16 (22) 18.75 4.83–72.73 <0.001
Both sides 2 (10) 0 (0) 2 (3) - - 0.07
Echocardiography performed 20 (100) 53 (98) 73 (99) - - 1.00
TTE 20 (100) 52 (96) 72 (97) - - 1.00
TEE 9 (45) 40 (74) 49 (66) 0.29 0.10–0.84 0.03
Echocardiographyc
Vegetation 14 (70) 25 (47) 39 (53) 0.26 0.87–7.84 0.16
Regurgitationd 17 (85) 35 (66) 52 (71) 2.91 0.75–11.27 0.15
Valve perforation 1 (5) 0 (0) 1 (1) - - 0.27
Paravalvular or intracardiac abscess 1 (5) 2 (4) 3 (4) 1.34 0.12–15.67 1.00
Duration of bacteremia before diagnosis, median days (range) 2 (0–8) 3 (0–28) 3 (0–28) - - 0.67
NOTE. Data are no. (%) of patients, unless otherwise indicated. TTE, transthoracic echogardiography; TEE, transesophageal echogardiography.
a Classified by modified Duke criteria.
b Includes abnormal echocardiographic manifestations both in native valve or in prosthetic valve.
c Represents initial echocardiographic findings with TTE alone or with both TTE and TEE.
d Regurgitation observed on echocardiogram in any cardiac valve at the time of diagnosis of endocarditis.BMC Infectious Diseases 2006, 6:137 http://www.biomedcentral.com/1471-2334/6/137
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incidence was slightly lower than that reported previously
(from 70% to 90%) [2,13,19,30]. We presented that the
frequency of left-sided involvement in addicts was as high
as 30% which is similar to that in some studies [2,10,31],
but higher than in most earlier reports with left-sided
endocarditis ranging from 8% to 19% [16,26,30]. In
IDUs, both sides of the heart are usually involved simul-
taneously in 5% to 10% of cases as detected in the current
trial.
Extracardiac deep infections have been associated with
SAB in left-sided endocarditis with the incidence ranging
from 40% to 76% [20,32-34] [see Additional file 1]. In
contrast to previous studies [13,26,35], deep infections in
our trial occurred in over 80% in both IDUs and nonad-
dicts. Systemic thromboembolic events are well recog-
nized complications in endocarditis occurring in 21% to
50% of cases, especially in patients with left-sided
involvement and prosthetic heart valves, and are accom-
panied by high mortality rates [36-39]. In earlier reports,
IDUs had fewer arterial emboli or strokes than nonaddicts
probably due to involvement of right-sided endocarditis
[2,18,40]. In contrast, in our trial arterial thromboem-
bolic events were observed with equal frequency in
addicts and in nonaddicts. Venous embolic events were
more common among addicts, and septic pulmonary
embolism manifestated only in IDUs. However, the fre-
quency of septic pulmonary embolism (40%) was less
than the previously reported incidence of 67% to 87% in
IDUs [40-42].
Due to lack of controlled studies, indications for surgical
approaches are not determined in patients with drug
addiction [27]. Furthermore, doubts on compliance and
continued drug abuse may reduce enthusiasm for surgery.
Cardiac surgery is thought to be needed in only a small
minority of cases in IDUs, and indications for surgical cor-
rection of right-sided involvement are not equally defined
as for left-sided endocarditis [16,41,43]. However, some
studies suggest that surgical treatment may clearly
improve survival in IE among IDUs [10,44]. In this trial,
cardiac surgery was as common in IDUs as in nonaddicts
(15% vs 7%), but valve repair was performed more often
in addicts. The frequency of cardiac surgery in IDUs was
high in light of prosthetic valve domination in nonaddicts
in agreement with another recent study [2].
The duration of parenteral antibiotic treatment in SAB
depends largely on the presence of an associated IE, in
which 4 to 6 weeks therapy is recommended [15,45,46].
A shorter 2 weeks treatment has been suggested for
selected cases of right-sided involvement with a good
prognosis [17,45]. Recommendations on duration of
aminoglycoside are variable. For left-sided native valve
endocarditis 3–5 days therapy is suggested but as long as
2 weeks for right-sided involvement has been used
Table 4: Clinical manifestations of injection drug users and nonaddicts with Staphylococcus aureus endocarditis during 3 months follow-
up.
Injection drug users Nonaddicts Total
Variable (n = 20) (n = 54) (n = 74) OR 95% CI P
Skin or soft tissue 12 (60) 34 (63) 46 (62) 0.88 0.31–2.53 1.00
Central intravenous catheter 0 (0) 3 (6) 3 (4) - - 0.56
Extracardiac deep infectiona 17 (85) 48 (89) 65 (88) 0.71 0.16–3.15 0.70
Pneumonia 14 (70) 27 (50) 41 (55) 2.33 0.78–6.98 0.19
Deep-seated abscessb 7 (35) 25 (46) 32 (43) 0.63 0.22–1.81 0.44
Osteomyelitis 6 (30) 17 (32) 23 (31) 0.93 0.31–2.85 1.00
Septic arthritis 3 (15) 5 (9) 8 (11) 1.73 0.37–8.02 0.67
Urinary tract 1 (5) 4 (7) 5 (7) 0.66 0.07–6.27 1.00
Recurrent S. aureus bacteremia 1 (5) 1 (2) 2 (3) 2.79 0.17–46.84 0.47
Mediastinitis 0 (0) 9 (17) 9 (12) - - 0.10
Vascular phenomenon 12 (60) 19 (35) 31 (42) 2.76 0.96–7.93 0.07
Arterial thromboembolic event 5 (25) 17 (32) 22 (30) 0.73 0.23–2.32 0.78
Heartc 0 (0) 11 (20) 11 (15) - - 0.03
Spleen, kidney or liver 3 (15) 0 (0) 3 (4) - - 0.02
Cerebral 4 (20) 9 (17) 13 (18) 1.25 0.34–4.63 0.74
Venous thromboembolic event 8 (40) 4 (7) 12 (16) 8.33 2.15–32.32 0.002
Pulmonary embolismd 8 (40) 2 (4) 10 (14) 17.33 3.26–92.24 <0.001
Deep venous thrombosis 0 (0) 2 (4) 2 (3) - - 1.00
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a Each patient has been included once although some patients had several extracardiac deep infections at various time points.
b Intramuscular, epidural, cerebral, parenchymal, lung, peritoneal, subphrenic, gynecological and pericardial abscesses, or pleural empyema.
c Acute myocardial infarction or unstable angina.
d Includes 8 patients with septic pulmonary embolism and 2 patients with venous pulmonary embolism.BMC Infectious Diseases 2006, 6:137 http://www.biomedcentral.com/1471-2334/6/137
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[47,48]. In addition, two small studies have demonstrated
oral fluoroquinolone and rifampicin for 4 weeks to be as
effective as the standard intravenous therapy in right-
sided endocarditis [49,50]. In our cohort, the high pro-
portion of extracardiac deep infections in addicts
extended the intravenous antibiotic therapy to 4 weeks.
This observation suggest that deep infections should be
actively searched for also among IDUs.
This trial was not designed to reveal possible differences
between antibiotic treatments and the statistical power
would neither enable such analysis. However, in accord-
ance with positive results in experimental and animal
studies we found lower mortality in SAB with a deep infec-
tion when the patients were treated with rifampicin in
addition to standard treatment [20] [see Additional file 1].
In the present trial, most IDUs were also treated with
rifampicin which might cause problems with drug interac-
tions not least with methadone.
Overall mortality rate was significantly higher among
nonaddicts (39%) than in addicts (10%) in accordance
with 30% to 70% mortality previously reported in nonad-
dicts [1,5,14]. In earlier studies, poor prognosis has been
associated with left-sided involvement, endocarditis of
prosthetic valve, higher incidence of underlying diseases,
central nervous system manifestations, and older age
[1,14,19,29]. Our trial showed that injection drug abuse
in accordance with younger age and lack of severe under-
lying diseases were associated with better prognosis. There
was a tendency for lower mortality in patients with right-
sided IE but for higher mortality in patients with severe
sepsis, left-sided involvement, and arterial embolic
events. However, these factors did not achieve statistical
significance probably due to insufficient sample size.
Conclusion
We concluded that endocarditis was more frequently con-
nected to SAB among IDUs. In contrast to previous
reports, addicts had equally often complications includ-
ing extracardiac deep infections and arterial thromboem-
bolic events as nonaddicts. In spite of this, mortality was
significantly lower in IDUs in accordance with earlier
data.
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